PMA device
HepQuant SHUNT® Liver Diagnostic Test
Hepquant, LLC · Test For Esophageal Varices (SIO, Class III) · First FDA decision Jun 18, 2026, newest Jun 18, 2026Gastrointestinal bleedingLiver disease and liver cancer
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
19
Naming "SHUNT Liver"
MAUDE reports
0
Brand "SHUNT Liver", since 2015
PubMed studies
23
Mentioning "SHUNT Liver"
AI summary across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
FDA decisions
The newest 1 of 1 decisions filed under this name.
P220016 · Decided Jun 18, 2026 · 1,373 days after receipt
Device type: Test for Esophageal Varices (SIO) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Injection Sclerotherapy for Esophageal Variceal BleedingNational determinationOn the books100.10Updated Apr 17, 2020
Clinical trials
Device studies on ClinicalTrials.gov that name "SHUNT Liver", any status and sponsor, newest update first.
University of California, Los AngelesAcademic, hospital or other
NCT04315571 · 68 participants · Start Mar 24, 2020 · Primary completion Apr 1, 2026
Device: Gore® Viatorr® Endoprosthesis with controlled expansion · For: Hypertension, Portal; Ascites
Sites: Los Angeles, California
- Freiburg TIPS RegistryRecruiting
University Hospital FreiburgAcademic, hospital or other
NCT05782556 · 2,000 participants (planned) · Start Jan 1, 2023 · Primary completion Dec 31, 2033
Device: Implantation of a transjugular intrahepatic portosystemic shunt (TIPS) · For: Liver Cirrhosis; Portal Hypertension; Non-Cirrhotic Portal Hypertension and 3 more
Sites: Freiburg im Breisgau, Germany
- Affordable Made-in-India Microspheres for Liver Cancer TherapyNot yet recruiting
Post Graduate Institute of Medical Education and Research, ChandigarhAcademic, hospital or other
NCT07436988 · 18 participants (planned) · Start Feb 15, 2026 · Primary completion Jul 31, 2028
Device: 90Y-Theraspheres; 188Re-Microspheres · For: Hepatecellular Carcinoma
Sites: Chandigarh, India; Mumbai, India; Bhubaneswar, India · 5 sites in all
- Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular Carcinoma.Terminated
Terumo Europe N.V.Public (4543.T)
NCT05451862 · 6 participants · Start Aug 21, 2023 · Primary completion May 27, 2025
Device: Holmium-166 treatment; Holmium-166 work-up · For: Hepatocellular Carcinoma
Sites: Augsburg, Germany; Munich, Germany
Boston Scientific CorporationPublic (BSX)
NCT04069468 · 1,247 participants · Start Mar 13, 2019 · Primary completion Dec 31, 2024
Device: TheraSphere · For: Hepatocellular Carcinoma
Sites: Amiens, France; Angers, France; Besançon, France · 37 sites in all
Seoul St. Mary's HospitalAcademic, hospital or other
NCT05639309 · 40 participants · Start Jan 13, 2023 · Primary completion Mar 31, 2025
Device: near-infrared spectroscopy based cerebral/somatic oximeter system (INVOS™ system manufactured by Medtronics) · For: Patent Ductus Arteriosus; Circulation; Newborn Morbidity and 1 more
Sites: Seoul, South Korea
Montefiore Medical CenterAcademic, hospital or other
NCT06144827 · 0 participants · Start Jan 2025 · Primary completion Jan 2028
Device: Multiparametric MRI scans; Multiparametric MRI scans + HepQuantShunt Test · For: Cancer, Hepatocellular; Radiotherapy Side Effect
Argon Medical DevicesNot on our public-company list
NCT05765253 · 3 participants · Start Jul 13, 2023 · Primary completion Oct 16, 2023
Device: Scorpion Portal Vein Access Kit; Cook Transjugular Liver Access Set · For: Portal Hypertension; Liver Diseases; Ascites Hepatic and 2 more
Sites: Atlanta, Georgia; New York, New York; Chapel Hill, North Carolina
University of Illinois ChicagoAcademic, hospital or other
NCT04044248 · 8 participants · Start Apr 4, 2019 · Primary completion Jun 18, 2024
Device: TIPS-obliteration · For: Cirrhosis, Liver; Hypertension, Portal; Esophageal and Gastric Varices and 2 more
Sites: Chicago, Illinois
- Small Diameter TIPS in Patients with Severe Liver Atrophy and Variceal BleedingPivotal-lookingNot yet recruiting
Huang MingshengAcademic, hospital or other
NCT06589531 · 120 participants (planned) · Start Sep 15, 2024 · Primary completion Aug 15, 2027
Device: During TIPS operation, shunt diameter or diameter of covered stent; During TIPS operation, shunt diameter or diameter of covered stent · For: Portal Hypertension Related to Cirrhosis
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "SHUNT Liver", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code SIO
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "SHUNT Liver"[tiab]. The summary above synthesizes these.
- Hyperammonemia and neonatal cardiac failure.
Adamovic T, Jouvet P, Vobecky S, et al. · Minerva Anestesiol · 2011Case Reports, Review
- Management of medically refractory ascites.
Zervos EE, Rosemurgy AS · Am J Surg · 2001Review
- Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes.
Yang XQ, Ye J, Li X, et al. · World J Gastroenterol · 2019Review
- Liver atrophy and encephalopathy after portacaval shunt in the rat.
Castaing D, Beaubernard C, Ariogul O, et al. · Eur Surg Res · 1982Research Support, Non-U.S. Gov't
- Diagnosis and Therapy of Visceral Vein Thrombosis: An Update Based on the Revised AWMF S2k Guideline.
Mühlberg KS · Hamostaseologie · 2024Review
- Predictors and Outcomes of Post-transjugular Intrahepatic Portosystemic Shunt Liver Failure in Patients with Cirrhosis.
Mukund A, Aravind A, Jindal A, et al. · Dig Dis Sci · 2024
- Cardiac Dysfunction in Patients with Liver Cirrhosis.
Karki N, Kc S, Sharma D, et al. · J Nepal Health Res Counc · 2019
- Heparin-mediated extracorporeal low-density lipoprotein precipitation: rationale for a specific adjuvant therapy in cardiovascular disease.
Blessing F, Wang Y, Walli AK, et al. · Transfus Apher Sci · 2004Review
- Congenital portacaval shunt in rats: liver adaptation to lack of portal vein--a light and electron microscopic study.
Bioulac-Sage P, Saric J, Boussarie L, et al. · Hepatology · 1985Research Support, Non-U.S. Gov't
- Transient hepatic attenuation differences on dynamic computed tomography.
Itai Y, Hachiya J, Makita K, et al. · J Comput Assist Tomogr · 1987Case Reports
- Significance and therapeutic potential of prostaglandin E2 receptor in hepatic ischemia/reperfusion injury in mice.
Kuzumoto Y, Sho M, Ikeda N, et al. · Hepatology · 2005Research Support, Non-U.S. Gov't
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.